Selecting @entity14 ( @entity14 ) @entity1 likely to respond to therapy remains a clinical challenge. The objectives of this study were to establish which genes were differentially expressed with respect to treatment sensitivity and relate this to copy number in a panel of 15 @entity14 cell lines. Copy number variations of the identified genes were assessed in a cohort of CRCs. IC50's were measured for @entity1487 , @entity901 , and @entity28910 , a PI3K/ @entity3470 inhibitor. Cell lines were profiled using array comparative genomic hybridisation, Illumina gene expression analysis, reverse phase protein arrays, and targeted sequencing of @entity984 hotspot mutations. Frequent gains were observed at 2p, 3q, 5p, 7p, 7q, 8q, 12p, 13q, 14q, and 17q and losses at 2q, 3p, 5q, 8p, 9p, 9q, 14q, 18q, and 20p. Frequently gained regions contained @entity470 , @entity10160 , MYC, @entity2751 , @entity14960 , @entity13031 , and @entity2674 , while frequently lost regions contained @entity21900 and @entity41677 . @entity14960 was selected for further study. Gene enrichment analysis showed that differentially expressed genes with respect to treatment response were involved in Wnt signalling, EGF receptor signalling, apoptosis, cell cycle, and angiogenesis. Stepwise integration of copy number and gene expression data yielded 47 candidate genes that were significantly correlated. @entity55705 was differentially expressed in all three treatment responses. Tissue microarrays were constructed for a cohort of 118 @entity14 @entity1 and @entity14960 and MYC amplifications were measured using fluorescence in situ hybridisation. @entity14960 and MYC were amplified in 14.5% and 7.4% of the cohort, respectively, and these amplifications were significantly correlated (p <=0.0001). @entity14960 protein expression in the @entity1 cohort was significantly correlated with @entity7952 , @entity584 , and @entity522 expression. In conclusion, a set of candidate predictive biomarkers for @entity1487 , @entity901 , and @entity28910 are described that warrant further study. Amplification of the putative oncogene @entity14960 has been described for the first time in a cohort of @entity14 @entity1 .

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of XXXX Cell Lines to Identify Novel Biomarkers.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity28910 :: ('MESH:C531198', 'Chemical') :: ['BEZ235', 'BEZ-235'] @entity522 :: ('836', 'Gene') :: ['Caspase 3'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity2674 :: ('675', 'Gene') :: ['BRCA2'] @entity2751 :: ('6608', 'Gene') :: ['SMO'] @entity55705 :: ('10016', 'Gene') :: ['PDCD6'] @entity584 :: ('207', 'Gene') :: ['Akt'] @entity7952 :: ('9451', 'Gene') :: ['pERK'] @entity3470 :: ('21977(Tax:10090)', 'Gene') :: ['mTOR'] @entity13031 :: ('8321', 'Gene') :: ['FZD1'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer', 'CRC'] @entity41677 :: ('140733', 'Gene') :: ['MACROD2'] @entity14960 :: ('10221', 'Gene') :: ['TRIB1'] @entity10160 :: ('5290', 'Gene') :: ['PIK3CA'] @entity21900 :: ('2272', 'Gene') :: ['FHIT'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Cancer']
